Imec

Quick links to important sections

Imec

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imec

Quick Facts

Property Description
Active ingredient Ivermectin
Form Oral tablet, Solution for injection, Topical cream/lotion
Pharmacological class Anthelmintic, Antiparasitic agent
General purpose Treats infections caused by internal and external parasites
Origin Semisynthetic (derived from Streptomyces avermitilis)

What Type of Medication is Imec (Ivermectin)?

Imec is a prescription-only medicine defined by its single active ingredient, Ivermectin (INN), which is classified by the World Health Organization (WHO) as an essential Anthelmintic. The compound belongs to the potent macrocyclic lactone class, which is clinically recognized for its high, selective efficacy against numerous parasitic diseases.

Ivermectin is a semisynthetic derivative of the avermectins, substances originally isolated from the fermentation products of the soil bacterium Streptomyces avermitilis. The medicine’s general purpose is to provide highly specific relief from parasitic burdens, such as those causing Strongyloidiasis (threadworm infection) or superficial infestations like Scabies.

Composition and Available Forms of Imec

The medicinal core of Imec is the Ivermectin compound, and its identity is shaped by the range of its pharmaceutical preparations. To ensure targeted therapy, Imec is available as an orally administered tablet for systemic action, or in various external preparations such as a topical cream or lotion. This formulation flexibility is a key factor, enabling use for both internal infections and dermal conditions. Excipients, like Benzyl alcohol in the injection solution, are integrated to ensure the stability and viability of the active ingredient across these diverse forms, underscoring its broad therapeutic utility.

What side effects are possible with Imec?

Possible Side Effects of Imec

Imec (Ivermectin) is generally well-tolerated, but like all medications, it can cause side effects. These side effects are often mild and temporary. The frequency and type of adverse reaction can depend on the condition being treated and the body's response to the dying parasites.

Common Side Effects

Commonly reported side effects may include:

  • Gastrointestinal issues: Nausea, vomiting, diarrhea, abdominal pain, or loss of appetite.
  • Neurological effects: Dizziness, drowsiness, or headache.
  • General symptoms: Fatigue, fever, or weakness.
  • Skin and muscular reactions: Skin rash, itching (pruritus), muscle aches, or joint pain.
System Common Side Effects (Examples)
Gastrointestinal Nausea, Diarrhea, Abdominal Pain
Nervous System Dizziness, Drowsiness, Headache
General/Other Fever, Fatigue, Rash, Itching

Serious Reactions and Safety Warnings

Seek immediate medical attention if you experience signs of a serious allergic reaction, such as difficulty breathing, swelling of the face, tongue, or throat, or hives. Severe skin reactions, including blistering or peeling, are rare but require urgent care.

Neurological Effects: In patients with heavy infection of the Loa loa parasite (Loiasis), taking Imec can lead to serious adverse effects affecting the brain, known as encephalopathy. Patients should be tested for this co-infection before treatment if they have lived in or traveled to Loa loa-endemic regions.

Pregnancy and Breastfeeding: Imec is generally not recommended during pregnancy unless the potential benefit outweighs the risk to the fetus. The drug passes into breast milk in low concentrations, so caution is advised, and consultation with a healthcare provider is essential for pregnant or breastfeeding individuals.

Other Warnings: The medication may cause dizziness or drowsiness; therefore, patients should exercise caution when driving or operating heavy machinery until they know how Imec affects them.

Overdose and Emergency Response

The official regulatory profile for Imec overdose is defined by specific systemic and neurological manifestations, dictating the need for immediate emergency action in severe cases.

Overdose Manifestations and Severe Outcomes

Documented clinical manifestations of overdose often involve the gastrointestinal and nervous systems. Initial signs may include nausea, vomiting, diarrhea, stomach pain, dizziness, headache, weakness, and loss of coordination (ataxia). Neurological toxicity can escalate to serious conditions, presenting as severe sleepiness, confusion, stupor, or changes in consciousness. Severe, life-threatening outcomes documented in regulatory sources include seizures, coma, and hypotension (low blood pressure). The use of highly concentrated veterinary formulations is associated with an increased risk of toxicity.


Emergency Action and Required Management

Individuals must seek immediate medical attention for any suspected overdose. Regulators mandate that emergency services must be contacted immediately if severe symptoms, such as collapse, a seizure, or an inability to be awakened, are observed. Management is strictly symptomatic and supportive because no specific antidote is known. Supportive care may involve procedures such as gastric decontamination, intended to manage the severe clinical effects, which include cardiovascular and CNS depression, until the compound is cleared.

Therapeutic Uses of Imec

What Imec Treats: Main Uses and Benefits

Imec is a medication generally used to contribute to easing the overall symptom load and supports patients during difficult episodes. The medication may be part of symptomatic management applied in addressing symptoms related to physical discomfort and conditions that involve heightened physiological activity, such as fever. It is relevant in contexts marked by increased discomfort or tension.

Quick Fact: Relief for Acute Discomfort

Managing Acute Symptom Escalation

Imec is commonly used in clinical settings that involve acute or unstable symptom patterns, such as when symptoms related to heightened physiological activity suddenly intensify. It may be applied across domains where additional symptomatic support is needed and generally supports patients during episodes of heightened discomfort.

Support for Disruptive Symptom Patterns

Imec is relevant when symptom clusters that may become intense or disruptive interfere with daily comfort. It helps address groups of symptoms that create noticeable functional strain and is applicable in conditions characterized by periods of heightened symptoms, which may assist with general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview on Ibuprofen

Eligibility and Restrictions for Use

Eligibility for Imec (Ivermectin) Use

Official regulatory documentation defines the eligible patient population for Imec by establishing strict exclusions, minimum age/weight criteria, and requirements for conditional use.

Eligibility Status Official Regulatory Rule
Absolute Contraindication Patients with known hypersensitivity or allergy to Ivermectin or any component of the formulation must not use the medicine [FDA, WHO].
Pediatric Exclusion The medicine is not established for use in children weighing less than 15 kg (approximately 33 lbs) due to insufficient safety data [FDA].
Reproductive Restrictions Use during pregnancy is not recommended as safety has not been established. Use in lactating mothers requires a risk-benefit assessment, as the medicine is excreted in breast milk [FDA].
Conditional Use Patients with co-existing conditions, such as those with significant Loa loa exposure, require mandatory pretreatment assessment and careful follow-up due to the risk of serious complications [FDA].

Eligibility is generally confirmed for adults and children weighing 15 kg or more for labeled indications. Geriatric patients are permitted to use the medicine but require caution due to the greater frequency of potential age-related organ dysfunction [WHO].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Imec is primarily structured around pharmacokinetic and pharmacodynamic influences documented in authoritative regulatory sources.


Kinetic and Pharmacodynamic Influences

Imec is a substrate and inhibitor of the P-glycoprotein (P-gp) efflux transporter and is metabolized principally by the CYP3A4 enzyme. Co-administration with strong P-gp inhibitors (such as Amiodarone or Clarithromycin) and potent CYP3A4 inhibitors may increase the systemic exposure (AUC/Cmax) of Imec, a finding which requires monitoring.

Pharmacodynamic interactions are noted with Warfarin, where co-administration has been associated with increased anticoagulant activities, including post-marketing reports of elevated INR. Furthermore, Imec carries a risk of additive CNS effects when co-administered with alcohol or other CNS depressant substances.


Interaction-Related Constraints

The oral formulation's systemic absorption is significantly increased (approximately 2.5-fold) when taken with a high-fat meal. This documented food interaction dictates that the oral tablet must be taken on an empty stomach to ensure a consistent pharmacokinetic profile. Caution is also noted for patients with high Loa loa microfilaria counts, as they are at an increased risk of serious CNS events following treatment.

Mechanism of Action

Selective Ion Channel Agonism

Imec's mechanism of action begins with its role as an agonist at glutamate-gated chloride channels ( GluCls), which are specific structures located on the nerve and muscle cells of susceptible organisms. This binding event modifies the channel's conformation, resulting in a significant influx of chloride ions ( Cl^-) across the cell membrane.


Disruption of Neuro-Muscular Signaling

The altered ion flow leads to hyperpolarization of the target cells. This negative shift in membrane potential prevents the generation of the necessary electrical impulses required for signal transmission between motor neurons and muscle fibers. The resulting cascade is the cessation of motor activity and flaccid paralysis of the affected organism.


Mechanistic Selectivity Constraint

The mechanism is constrained by the drug's inherent selectivity for the invertebrate GluCls and the limited accessibility to the host's central nervous system. This ensures the powerful ion channel modulation is largely contained to the target organism, resulting in a specific physiological consequence.

Dosage and Administration Information

How to Use Imec

Imec (Ivermectin) is administered through one of two officially approved routes of administration: the oral route for systemic infections or the topical route for external conditions. The general principle for using the oral tablet is to administer the entire treatment regimen based on a weight-calculated single dose, separate from mealtimes.

Official Dosing and Administration Schedules

The dosage of the 3 mg oral tablet is precisely calculated according to the patient's body weight (kg) for the specific labeled use. This weight-based approach determines the exact number of tablets required for the prescribed course.

Indication Labeled Dosing Regimen (Approximate) Frequency Pattern Key Contextual Instruction
Strongyloidiasis Single dose of 200 mcg/kg body weight Single-dose therapy Must be taken on an empty stomach
Onchocerciasis Single dose of 150 mcg/kg body weight Intermittent (e.g., every 3 –12 months) Must be taken on an empty stomach

For oral administration, the tablets must be taken with water, ensuring that the medicine is administered on an empty stomach (at least one hour before or two hours after a meal) to optimize absorption. The tablet is approved for use only in children weighing 15 kg or more; where swallowing is difficult, the tablets should be crushed prior to administration.

If the medicine is used for conditions requiring topical application, such as the lotion form, official instructions specify that the product should be left on the affected area for a specific duration, such as 10 minutes, before being rinsed. The oral treatment for Strongyloidiasis is typically a short-term, single course, while treatment for Onchocerciasis involves an intermittent schedule of single doses repeated periodically over time to control the parasitic lifecycle.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Imec (Ivermectin)

This section provides a summary of the clinical research and scientific evidence that relates to the use of Imec, focusing on findings from high-quality studies like randomized controlled trials and systematic reviews, as published by official sources.


Evidence for use in Strongyloidiasis (Intestinal Threadworm Infection)

Research for this condition, caused by the parasite Strongyloides stercoralis, primarily relies on controlled clinical trials and large observational cohort studies. Studies examined parasitological cure, which is measured by the sustained absence of the parasite (larvae or DNA) in stool samples over defined time intervals. Trials explored comparison by monitoring these outcomes against other antiparasitic agents.

Studies also examined the resolution of symptoms related to physical discomfort and outcomes linked to inflammatory states. Findings describe patterns observed in the studies related to the time measured until the parasite was no longer detectable, and studies reported how symptoms evolved in the observed populations.

Evidence for use in Scabies (Dermal Mite Infestation)

Research for Scabies, a contagious skin infestation caused by mites, is derived from data in Randomized Controlled Trials (RCTs) and systematic reviews that synthesize the trial data. Studies explored comparison of oral Imec to established topical treatments, such as permethrin, and monitored for outcomes related to Clinical Cure. This cure was defined as the complete clearance of skin lesions, burrows, and/or the absence of the mite itself upon examination. Community-based research has also explored the effect of mass administration of Imec on community-wide prevalence rates.


What Research Gaps and Uncertainties Remain

The broad evidence landscape for Imec is based on research derived from many trials, but evidence highlights what is known—and what is still uncertain. One key research limitation is the variability in diagnostic methods used across Strongyloidiasis studies, which complicates the uniform definition of "cure" in different study reports.

Data for certain patient groups remain insufficient. For instance, children weighing less than 15 kg are typically absent from many of the large-scale efficacy trials. Similarly, evidence is limited regarding the use of Imec in pregnant or breastfeeding individuals for these indications, and these groups are often not included in the main clinical trials. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Ivermectin Substipharm 3 mg tablets Public Assessment Report (Based on EU regulatory procedure, indicated for Scabies and Strongyloidiasis)

Frequently Asked Questions (FAQ)

Common questions about Imec (FAQ)


Q: Can Imec be taken with over-the-counter pain relievers like ibuprofen?

A: Official product information does not list a specific known interaction between Imec and common over-the-counter pain relievers such as ibuprofen. Regulatory agencies emphasize the importance of discussing all medicines and products with a healthcare provider, as a general precaution when co-administering any substance.


Q: How quickly should I expect to notice any effects from Imec?

A: The timeline for effects depends on the condition being treated. For onchocerciasis, a noticeable decrease in the microfilariae count in the skin is often observed within three days of treatment. For strongyloidiasis, efficacy is assessed by checking for the absence of the parasite's larvae approximately 3 to 4 weeks after the single-dose therapy.


Q: What happens if I forget to take a dose of Imec?

A: Treatment for most labeled conditions is designed as a single, weight-calculated dose. If the single treatment has not been taken, it is administered according to the prescription. If the medicine is prescribed on an intermittent schedule, the general recommendation is to seek guidance from the prescribing healthcare provider, as instructions for a missed dose can vary.


Q: Is it okay for people with kidney problems to use Imec?

A: According to official information, less than one percent of Imec is eliminated through the urine, as it is extensively metabolized by the liver. Therefore, based on available data, specific dose adjustments are not typically addressed for renal impairment in the product label. Nevertheless, a healthcare provider determines the appropriateness of the drug and any necessary monitoring, particularly given the limited data in this patient group.


Q: What kind of monitoring might be needed while on Imec?

A: If a patient has lived in or traveled to areas where the Loa loa parasite is common, mandatory pretreatment assessment is required before starting Imec. Additionally, official documents note that patients taking blood-thinning medication, such as Warfarin, may require monitoring of their International Normalized Ratio (INR) due to a possible interaction.


Q: Does taking Imec change your weight?

A: Weight change is not listed as a common or serious side effect in the official product labeling for Imec. Patient weight is primarily used by a prescriber to calculate the correct dose of the medicine for the specific condition being treated.


Q: Can Imec affect how my birth control works?

A: Official regulatory documents do not list a specific, direct interaction between Imec and hormonal birth control. However, Imec is known to be metabolized by the CYP3A4 enzyme. Since some oral contraceptives are also affected by changes to this enzyme system, discussion with a healthcare provider remains essential.


Q: How long does Imec stay in your system after stopping?

A: Official pharmacokinetic data indicates that the oral tablet has a plasma half-life of approximately 18 hours. The drug and its byproducts (metabolites) are primarily eliminated from the body through the feces over an estimated 12-day period.


Q: Can Imec cause changes to vision?

A: When used for certain specific indications like river blindness (Onchocerciasis), adverse effects affecting the eyes have been reported. These can include pain, redness, tearing, swelling of the eye or eyelids, and blurred vision. The occurrence of such changes is documented as a serious adverse event, which should be immediately reported to a healthcare provider.


Q: Are there any common foods or supplements that interact with Imec?

A: Yes, official prescribing information notes a key interaction with food. The systemic absorption of the oral tablet is significantly increased when taken with a high-fat meal. For this reason, the administration instructions specify that the medicine should be taken on an empty stomach.


Q: Do studies support the use of Imec in older adults?

A: Clinical trials often do not include a large enough number of participants aged 65 and older to make definitive statements on whether they respond differently. Official regulatory documents indicate that caution is generally observed when considering Imec for older adults, as they may have a higher frequency of age-related declines in organ function.


Q: What is the difference between Imec and the generic version?

A: The active ingredient in both the brand-name and generic versions of the medicine is Ivermectin. Generic products are required by regulatory bodies to meet the same quality, strength, purity, and performance standards as the original branded drug.


Q: Do I need to take Imec at a specific time of day?

A: The primary condition for taking the oral tablet is based on its relation to food consumption, rather than a specific time of day. It must be taken with water on an empty stomach—which means at least one hour before or two hours after eating a meal—to ensure optimal absorption.


Q: What is the official classification of Imec (e.g., controlled substance)?

A: Imec is officially classified as an Anthelmintic, which means it is used to treat parasitic worms. It is designated as a prescription-only medicine, and official regulatory sources in the US do not list it as a federally controlled substance.


Q: Does Imec interact with common herbal supplements like St. John's Wort?

A: Imec is broken down by the CYP3A4 enzyme in the body. While specific herbal supplements like St. John's Wort are not explicitly listed in the drug interactions section, substances that affect this enzyme may increase the amount of Imec in the body, which is a factor for healthcare providers to consider.


Q: What is the maximum duration of treatment mentioned in the drug information?

A: For Strongyloidiasis, treatment is a single-dose course. For Onchocerciasis, treatment involves an intermittent schedule where single doses are repeated periodically, often every 3 to 12 months, over time to manage the parasitic lifecycle. The official documents describe the required pattern of use but do not specify a maximum total duration over a lifetime.


Q: Does Imec interact with common cold or flu medicines?

A: Official labeling does not list specific common cold or flu medicines, but it does note that Imec interacts with substances that affect the P-glycoprotein transporter or the CYP3A4 enzyme. Additionally, caution is generally noted when taking Imec with any substances that have central nervous system (CNS) depressant effects.


Q: What kind of lab tests are recommended before starting Imec?

A: A mandatory pretreatment assessment is required if there is a possibility of co-infection with the Loa loa parasite. While routine general lab tests are not universally mandated in the label, special monitoring, such as INR levels, is needed for patients taking blood thinners like Warfarin.


Q: What are the common reasons people discontinue Imec treatment?

A: Discontinuance is frequently related to the occurrence of adverse events, or side effects, which are described in studies as often being mild and temporary. In rare cases, the occurrence of a serious reaction, especially in patients with high Loa loa infection, would require immediate cessation of the drug.


Q: Does Imec have any known interaction with grapefruit?

A: The label does not explicitly name grapefruit; however, grapefruit is a strong inhibitor of the CYP3A4 enzyme. Since Imec is metabolized by CYP3A4, consuming grapefruit or its juice could potentially increase the overall exposure of Imec in the body.


How should Imec be stored and disposed of?

How to Store and Dispose of Imec

Official regulatory guidelines define specific conditions for storing and disposing of Imec (Ivermectin) to maintain stability and ensure safety.

Storage Requirements

Imec tablets must be stored at or below a maximum temperature, typically not above 25 C or 30 C, depending on the formulation. The medicine must be kept in the original package to ensure protection from light and stored away from moisture. Containers must remain tightly closed.

Child Safety and Disposal

It is a mandatory regulatory requirement to keep this medicine out of the sight and reach of children. For disposal, any unused or expired product must be discarded in accordance with local requirements. Due to the active ingredient's environmental toxicity, the product must not be flushed into surface water or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imec found in:

A-Z Index: